Quality of Life in People With Multiple Sclerosis Receiving Glatiramer Acetate Or Interferon in Greek Clinical Practice

References

• Klineova S , LublinFD. Clinical course of multiple sclerosis. Cold Spring Harb. Perspect. Med., 8(9), a028928 (2018).
   PubMed Web of Science ®Google Scholar
• Metaxakis A , PetratouD, TavernarakisN. Molecular interventions towards multiple sclerosis treatment. Brain Sci., 10(5), 299 (2020).
   PubMed Web of Science ®Google Scholar
• Smith AL , CohenJA, HuaLH. Therapeutic targets for multiple sclerosis: current treatment goals and future directions. Neurotherapeutics, 14(4), 952–960 (2017).
   PubMed Web of Science ®Google Scholar
• Comi G , AmatoMP, BertolottoAet al. The heritage of glatiramer acetate and its use in multiple sclerosis. Mult. Scler. Demyelinating Disord., 1, 6 (2016).
   Google Scholar
• Jakimovski D , KolbC, RamanathanM, ZivadinovR, Weinstock-GuttmanB. Interferon β for multiple sclerosis. Cold Spring Harb. Perspect. Med., 8(11), a032003 (2018).
   PubMed Web of Science ®Google Scholar
• Kappos L , PolmanCH, FreedmanMSet al. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology, 67(7), 1242–1249 (2006).
   PubMed Web of Science ®Google Scholar
• Ford C , GoodmanAD, JohnsonKet al. Continuous long-term immunomodulatory therapy in relapsing multiple sclerosis: results from the 15-year analysis of the US prospective open-label study of glatiramer acetate. Mult. Scler., 16(3), 342–350 (2010).
   PubMed Web of Science ®Google Scholar
• Mitsikostas DD , GoodinDS. Comparing the efficacy of disease-modifying therapies in multiple sclerosis. Mult. Scler. Relat. Disord., 18, 109–116 (2017).
   PubMed Web of Science ®Google Scholar
• Armoiry X , KanA, Melendez-TorresGJet al. Short- and long-term clinical outcomes of use of beta-interferon or glatiramer acetate for people with clinically isolated syndrome: a systematic review of randomised controlled trials and network meta-analysis. J. Neurol., 265(5), 999–1009 (2018).
   PubMed Web of Science ®Google Scholar
• Papadopoulos D , MitsikostasDD. Oral disease-modifying treatments for relapsing multiple sclerosis: a likelihood to achieve no evidence of disease activity or harm analysis. CNS Drugs, 32(11), 1069–1078 (2018).
   PubMed Web of Science ®Google Scholar
• Pashazadeh Kan F , HoseinipalangiZ, AhmadiNet al. Global, regional and national quality of life in patients with multiple sclerosis: a global systematic review and meta-analysis. BMJ Support. Palliat. Care, 12(2), 158–166 (2022).
   PubMed Web of Science ®Google Scholar
• Gil-González I , Martín-RodríguezA, ConradR, Pérez-San-GregorioMÁ. Quality of life in adults with multiple sclerosis: a systematic review. BMJ Open, 10(11), e041249 (2020).
   PubMed Web of Science ®Google Scholar
• Nicholas JA , ElectricwalaB, LeeLK, JohnsonKM. Burden of relapsing–remitting multiple sclerosis on workers in the US: a cross-sectional analysis of survey data. BMC Neurology, 19(1), 258 (2019).
   PubMed Web of Science ®Google Scholar
• Hermann BP , VickreyB, HaysRDet al. A comparison of health-related quality of life in patients with epilepsy, diabetes and multiple sclerosis. Epilepsy Res., 25(2), 113–118 (1996).
   PubMed Web of Science ®Google Scholar
• Riazi A , HobartJC, LampingDLet al. Using the SF-36 measure to compare the health impact of multiple sclerosis and Parkinson’s disease with normal population health profiles. J. Neurol. Neurosurg. Psychiatry, 74(6), 710–714 (2003).
   PubMed Web of Science ®Google Scholar
• Jongen PJ . Health-related quality of life in patients with multiple sclerosis: impact of disease-modifying drugs. CNS Drugs, 31(7), 585–602 (2017).
   PubMed Web of Science ®Google Scholar
• Baumstarck K , BoyerL, BoucekineM, MichelP, PelletierJ, AuquierP. Measuring the quality of life in patients with multiple sclerosis in clinical practice: a necessary challenge. Mult. Scler. Int., 2013, 524894 (2013).
   PubMedGoogle Scholar
• Jongen PJ , LehnickD, SandersEet al. Health-related quality of life in relapsing remitting multiple sclerosis patients during treatment with glatiramer acetate: a prospective, observational, international, multi-centre study. Health Qual. Life Outcomes, 8, 133 (2010).
   PubMed Web of Science ®Google Scholar
• Jongen PJ , LehnickD, KoemanJet al. Fatigue and health-related quality of life in relapsing-remitting multiple sclerosis after 2 years glatiramer acetate treatment are predicted by changes at 6 months: an observational multi-center study. J. Neurol., 261(8), 1469–1476 (2014).
   PubMed Web of Science ®Google Scholar
• Ziemssen T , BajenaruOA, CarráAet al. A 2-year observational study of patients with relapsing-remitting multiple sclerosis converting to glatiramer acetate from other disease-modifying therapies: the COPTIMIZE trial. J. Neurol., 261(11), 2101–2111 (2014).
   PubMed Web of Science ®Google Scholar
• Ziemssen T , CalabreseP, PennerIK, ApfelR. QualiCOP: real-world effectiveness, tolerability, and quality of life in patients with relapsing–remitting multiple sclerosis treated with glatiramer acetate, treatment-naïve patients, and previously treated patients. J. Neurol., 263(4), 784–791 (2016).
   PubMed Web of Science ®Google Scholar
• Wolinsky JS , BorresenTE, DietrichDWet al. GLACIER: an open-label, randomized, multicenter study to assess the safety and tolerability of glatiramer acetate 40 mg three-times weekly versus 20 mg daily in patients with relapsing-remitting multiple sclerosis. Mult. Scler. Relat. Disord., 4(4), 370–376 (2015).
   PubMed Web of Science ®Google Scholar
• Miller DM , Weinstock-GuttmanB, BourdetteD, YouX, FouldsP, RudickRA. Change in quality of life in patients with relapsing–remitting multiple sclerosis over 2 years in relation to other clinical parameters: results from a trial of intramuscular interferon β-1a. Mult. Scler., 17(6), 734–742 (2011).
   PubMed Web of Science ®Google Scholar
• Freeman JA , ThompsonAJ, FitzpatrickRet al. Interferon-beta1b in the treatment of secondary progressive MS: impact on quality of life. Neurology, 57(10), 1870–1875 (2001).
   PubMed Web of Science ®Google Scholar
• Cohen JA , CutterGR, FischerJSet al. Benefit of interferon beta-1a on MSFC progression in secondary progressive MS. Neurology, 59(5), 679–687 (2002).
   PubMed Web of Science ®Google Scholar
• Ontaneda D , TallantyreE, KalincikT, PlanchonSM, EvangelouN. Early highly effective versus escalation treatment approaches in relapsing multiple sclerosis. Lancet Neurol., 18(10), 973–980 (2019).
   PubMed Web of Science ®Google Scholar
• Hellenic Ministry of Health . Diagnostic and therapeutic protocols for prescribing neurological diseases – multiple sclerosis (2018). www.moh.gov.gr/articles/health/domes-kai-draseis-gia-thn-ygeia/kwdikopoihseis/therapeytika-prwtokolla-syntagografhshs/diagnwstika-kai-therapeytika-prwtokolla-syntagografhshs/5414-diagnwstika-kai-therapeytika-prwtokolla-syntagografhshs-neyrologikwn-noshmatwn
   Google Scholar
• Polman CH , ReingoldSC, BanwellBet al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann. Neurol., 69(2), 292–302 (2011).
   PubMed Web of Science ®Google Scholar
• Krokavcova M , van DijkJPet al. Perceived health status as measured by the SF-36 in patients with multiple sclerosis: a review. Scand. J. Caring Sci., 23(3), 529–538 (2009).
   PubMed Web of Science ®Google Scholar
• Zorzon M , de MasiR, NasuelliDet al. Depression and anxiety in multiple sclerosis. A clinical and MRI study in 95 subjects. J. Neurol., 248(5), 416–421 (2001).
   PubMed Web of Science ®Google Scholar
• Simeoni M , AuquierP, FernandezOet al. Validation of the multiple sclerosis international quality of life questionnaire. Mult. Scler., 14(2), 219–230 (2008).
   PubMed Web of Science ®Google Scholar
• Smith J , BruceA, GlusmanM, ThelenJ, LynchS, BruceJM. Determining reliable change on the modified fatigue impact scale (5-item version). Mult. Scler. Relat. Disord., 20, 22–24 (2018).
   PubMed Web of Science ®Google Scholar
• Zavoreo I , GržinčićT, PreksavecM, MadžarT, BašićKes V. Sexual dysfunction and incidence of depression in multiple sclerosis patients. Acta Clin. Croat., 55(3), 402–406 (2016).
   PubMed Web of Science ®Google Scholar
• Meyer-Moock S , FengYS, MaeurerM, DippelFW, KohlmannT. Systematic literature review and validity evaluation of the Expanded Disability Status Scale (EDSS) and the Multiple Sclerosis Functional Composite (MSFC) in patients with multiple sclerosis. BMC Neurol., 14, 58 (2014).
   PubMed Web of Science ®Google Scholar
• Brazier JE , HarperR, JonesNMet al. Validating the SF-36 health survey questionnaire: new outcome measure for primary care. BMJ, 305(6846), 160–164 (1992).
   PubMed Web of Science ®Google Scholar
• Raimo S , TrojanoL, SpitaleriD, PetrettaV, GrossiD, SantangeloG. Psychometric properties of the Hamilton depression rating scale in multiple sclerosis. Qual. Life Res., 24(8), 1973–1980 (2015).
   PubMed Web of Science ®Google Scholar
• Litster B , FiestKM, PattenSBet al. Screening tools for anxiety in people with multiple sclerosis: a systematic review. Int. J. MS Care, 18(6), 273–281 (2016).
   PubMedGoogle Scholar
• D’Souza E . Modified fatigue impact scale – 5-item version (MFIS-5). Occup. Med., 66(3), 256–257 (2016).
   Google Scholar
• Metz LM , PattenSB, ArchibaldCJet al. The effect of immunomodulatory treatment on multiple sclerosis fatigue. J. Neurol. Neurosurg. Psychiatry, 75(7), 1045–1047 (2004).
   PubMed Web of Science ®Google Scholar
• EMA . Interferon (Rebif®). Summary of product characteristics. (2008). (Accessed 17June2022). www.ema.europa.eu/en/documents/product-information/rebif-epar-product-information_en.pdf
   Google Scholar
• EMC . Copaxone 20 mg/ml solution for injection in pre-filled syringe (2022). (Accessed 17June2022). www.medicines.org.uk/emc/product/183#gref
   Google Scholar
• Gklinos P , PapadopoulosD, MitsikostasDD. Nocebo in multiple sclerosis trials: a meta-analysis on oral and newer injectable disease-modifying treatments. Mult. Scler. Relat. Disord., 36, 101389 (2019).
   PubMed Web of Science ®Google Scholar